NDAORALTABLET
Approved
Nov 1942
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
DEMEROL (meperidine hydrochloride) by Gen Pharmaceuticals is morphine; the most prominent of these involve the central nervous system and organs composed of smooth muscle. Approved for pain severe enough to require an opioid analgesic, for which alternative treatments are inadequate. First approved in 1942.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DEMEROL (meperidine hydrochloride) is a synthetic opioid analgesic indicated for severe pain when alternative treatments are inadequate. It works as a mu-opioid receptor agonist, producing analgesia and sedation through central nervous system depression and effects on smooth muscle organs.
$0.071MPart D
LOE ApproachingDeclining
Small market ($71K annual spend, 187 claims) with declining trajectory indicates shrinking team and limited growth opportunities as product approaches loss of exclusivity.
Mechanism of Action
morphine; the most prominent of these involve the central nervous system and organs composed of smooth muscle. The principal actions of therapeutic value are analgesia and sedation.
Worked on DEMEROL at Gen Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.